Histogenics (HSGX) Tops Q1 EPS by 8c

Histogenics (NASDAQ: HSGX) reported Q1 EPS of ($0.27), $0.08 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Histogenics (HSGX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41